Biotech News
-
Awakn Life Sciences to Commence Trading on the OTC Market on July 26, 2021 Under the Symbol ‘AWKNF’
July 26, 2021 (Source) — Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) (‘Awakn’), a biotechnology company with…
-
DIAGNOS Announces the Official Opening of the AI Assisted Screening Clinic at Magrabi Hospital with the Presence of the Undersecretary of the Ministry of Health of Saudi Arabia
July 22, 2021 (Source) — Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A),…
-
Awakn Life Sciences Announces the Addition of Renowned Substance Addiction Researcher Professor Barbara Mason to Its Clinical Advisory Board
July 22, 2021 (Source) — Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing…
-
DIAGNOS initiates a clinical trial study in the USA for early detection and prevention of Stroke using its new application CARA-STROKE
July 20, 2021 (Source) — Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader…
-
Sixth Wave Commissions Pre-Production Affinity(TM) System
July 20, 2021 (Source) — Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or the…
-
XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio
July 20, 2021 (Source) — The acquisition creates significant commercial development and manufacturing opportunities for XPhyto as well…
-
Element Nutritional Sciences Announces Partnerships to Accelerate Distribution
July 20, 2021 (Source) — Advantage Solutions to expand retail partnership network Canopy Management to manage growth through…
-
Rritual Superfoods Issues Letter to Shareholders
July 15, 2021 (Source) — Rritual CEO & Director, Mr. David Kerbel, Delivers Comprehensive Progress Report, Increased 2021 Targets…
-
Element Nutritional Sciences Announces Rejuvenate™ Now Available at Sam’s Club
July 14, 2021 (Source) — Element Nutritional Sciences Inc. (CSE:ELMT; FRANKFURT:93X) (the “Company” or “Element”) is pleased to…
-
Awakn Life Sciences Initiates Research Program to Further Develop Ketamine-Assisted Therapies for Treating Addiction
July 14, 2021 (Source) — Program to Focus on Developing and Delivering New Treatments for Substance and Behavorial Addictions…
